Nuvalent announced that the FDA has granted breakthrough therapy designation to NVL-520 for the treatment of patients with ROS1-positive metastatic non-small cell lung cancer, or NSCLC, who have been previously treated with two or more ROS1 tyrosine kinase inhibitors, or TKIs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NUVL:
- Block upgraded, Rivian downgraded: Wall Street’s top analyst calls
- Baird starts Nuvalent at Outperform, sees ‘billion-dollar-plus opportunities’
- Nuvalent initiated with an Outperform at Baird
- Nuvalent initiates Phase 2 portion of ALKOVE-1 trial
- Nuvalent price target raised to $80 from $70 at Piper Sandler
